Venus Remedies

VENUSREM30 Apr 2024

Pharmaceuticals

₹

+0.10 (+0.03%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Venus Remedies

Venus Remedies

Pharmaceuticals

VENUSREM30 Apr 2024

₹

+0.10 (+0.03%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
20-May-2013	D	Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2013, inter alia, has : 1. Recommended a dividend @ of 30% i.e. Rs. 3/-per share for the financial year ended March 31, 2013, subject to approval of the same by shareholders at the Annual General Meeting.	23-Sep-2013
21-Jun-2012	D	Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 21, 2012, inter alia, has recommended a dividend @ 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2012 subject to approval of the same by shareholders at the Annual General Meeting.	20-Sep-2012
26-Jul-2011	D	Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 26, 2011, inter alia, has recommended a dividend @ of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2011 subject to approval of the same by shareholders at the Annual General Meeting.	22-Sep-2011
31-Jul-2010	D	Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 31, 2010, inter alia, has recommended a dividend of @ 30% i.e. Rs. 3/- per. share for the financial year ended March 31, 2010 subject to approval of the same by shareholders at the Annual General Meeting.	23-Sep-2010
21-Aug-2009	D	Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 21, 2009, inter alia, has transacted the following: 1. Recommended a dividend of @ 30% for the financial year ended March 31, 2009 subject to approval of the same by shareholders at the Annual General Meeting.	17-Sep-2009
29-Jul-2008	D	Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 29, 2008, inter alia, has transacted the following: Recommended a dividend @ of 40% for the financial year ended March 31, 2008 subject to approval of the same by shareholders at the Annual General Meeting.	12-Sep-2008
20-Aug-2007	D	Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meting held on August 20, 2007, inter alia, has recommended dividend @ of 30% for the financial year ended March 31, 2007 subject to the approval of the same by shareholders at the Annual General Meeting.	18-Sep-2007
02-Feb-2024	BC	VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. To consider and approve Unaudited Standa	14-Feb-2024
28-Oct-2023	BC	VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve This is to inform you that the meeting of B	09-Nov-2023
24-Aug-2023	BC	Proceedings of Annual General Meeting held today.	01-Oct-2023
15-Jul-2023	BC	Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th July 2023 1. Appointment of M/s J.K. Jain & Associates as the Statutory Auditors of the Company subject to the approval of members in	24-Aug-2023
14-Jul-2023	BC	Annual General Meeting	18-Aug-2023

Announcement Date20-May-2013

Ex Dividend Date23-Sep-2013

Dividend(%)30

Announcement Date21-Jun-2012

Ex Dividend Date20-Sep-2012

Dividend(%)30

Announcement Date26-Jul-2011

Ex Dividend Date22-Sep-2011

Dividend(%)30

Announcement Date31-Jul-2010

Ex Dividend Date23-Sep-2010

Dividend(%)30

Announcement Date21-Aug-2009

Ex Dividend Date17-Sep-2009

Dividend(%)30

Announcement Date29-Jul-2008

Ex Dividend Date12-Sep-2008

Dividend(%)40

Announcement Date20-Aug-2007

Ex Dividend Date18-Sep-2007

Dividend(%)30

No Rights has been declared by VENUSREM

Book Closure

Record Date	Split Date	Purpose
14-Feb-2024	-	VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. To consider and approve Unaudited Standa
09-Nov-2023	-	VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve This is to inform you that the meeting of B
01-Oct-2023	-	Proceedings of Annual General Meeting held today.
24-Aug-2023	-	Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th July 2023 1. Appointment of M/s J.K. Jain & Associates as the Statutory Auditors of the Company subject to the approval of members in
18-Aug-2023	01 Jan'1900	Annual General Meeting

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Venus Remedies Ltd ₹327.15(+0.10/0.03%)	327.15	+0.10	437.30	64.23	17.14	0.90
Astrazeneca Pharma India Ltd ₹5,341.25(-214.85/-3.87%)	5,341.25	-214.85	13,353.13	68.03	83.72	20.39
Bliss GVS Pharma Ltd ₹123.70(-0.75/-0.60%)	123.70	-0.75	1,295.03	60.30	18.97	1.32
Cipla Ltd ₹1,401.20(-6.35/-0.45%)	1,401.20	-6.35	113,132.18	52.94	34.40	4.37
Abbott India Ltd ₹26,415.75(+138.15/0.53%)	26,415.75	+138.15	56,133.47	18.05	49.00	18.06
Amrutanjan Health Care Ltd ₹697.95(-11.45/-1.61%)	697.95	-11.45	2,017.82	15.18	45.86	7.70

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	131.23	170.19	98.63	148.53	109.63	124.75
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	131.23	170.19	98.63	148.53	109.63	124.75
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	2.42	2.93	2.06	3.24	3.75	1.77
Total Income	133.65	173.12	100.69	151.77	113.38	126.52
Total Expenditure	118.23	157.06	85.16	127.50	102.55	109.58
PBIDT	15.42	16.06	15.53	24.27	10.83	16.94
Interest	0.00	0.00	0.00	0.00	0.00	0.00
PBDT	15.42	16.06	15.53	24.27	10.83	16.94
Depreciation	6.30	6.21	7.32	8.06	6.97	8.77
Tax	-0.23	3.68	3.39	0.00	0.00	0.00
Deferred Tax	1.16	0.72	0.48	8.67	1.25	0.44
Reported Profit After Tax	8.19	5.45	4.34	7.54	2.61	7.73
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	8.19	5.45	4.34	7.54	2.61	7.73

EPS (Unit Curr.)	6.13	4.07	3.25	5.64	1.95	5.78
EPS (Adj) (Unit Curr.)	6.13	4.07	3.25	5.64	1.95	5.78
Calculated EPS (Unit Curr.)	6.13	4.08	3.25	5.64	1.95	5.78
Calculated EPS (Adj) (Unit Curr.)	6.13	4.08	3.25	5.64	1.95	5.78
Calculated EPS (Ann.) (Unit Curr.)	24.50	16.31	12.98	22.56	7.81	23.13
Calculated EPS (Adj) (Ann.) (Unit Curr.)	24.50	16.31	12.98	22.56	7.81	23.13
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	13.37	13.37	13.37	13.37	13.37	13.37
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	11.75	9.44	15.75	16.34	9.88	13.58
PBDTM(%)	11.75	9.44	15.75	16.34	9.88	13.58
PATM(%)	6.24	3.20	4.40	5.08	2.38	6.20

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	143.42	167.72	95.15	155.64	116.90	139.89
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	143.42	167.72	95.15	155.64	116.90	139.89
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	2.35	3.05	2.26	3.41	3.81	1.79
Total Income	145.77	170.77	97.41	159.05	120.71	141.68
Total Expenditure	131.38	149.93	84.75	131.03	108.80	126.92
PBIDT	14.39	20.84	12.66	28.02	11.91	14.76
Interest	0.07	0.06	0.06	0.00	0.15	0.00
PBDT	14.32	20.78	12.60	28.02	11.76	14.76
Depreciation	6.54	6.44	7.55	8.29	7.22	8.99
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	-0.23	3.68	3.39	0.00	0.00	0.00
Deferred Tax	1.16	0.72	0.48	8.67	1.25	0.44
Reported Profit After Tax	6.85	9.94	1.18	11.06	3.29	5.33
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	6.85	9.94	1.18	11.06	3.29	5.33

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	6.85	9.94	1.18	11.06	3.29	5.33

EPS (Unit Curr.)	5.13	7.44	0.88	8.27	2.46	3.99
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	13.37	13.37	13.37	13.37	13.37	13.37

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	10.03	12.43	13.31	18.00	10.19	10.55
PBDTM(%)	9.98	12.39	13.24	18.00	10.06	10.55
PATM(%)	4.78	5.93	1.24	7.11	2.81	3.81

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	13.37	13.37	12.34	12.34	12.34	12.34
Reserves Total	464.68	436.05	374.09	319.91	328.61	355.65
Equity Share Warrants	0.00	0.00	13.75	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	478.05	449.42	400.18	332.25	340.95	367.99
Secured Loans	0.00	0.00	0.00	167.99	238.82	251.44
Unsecured Loans	38.68	38.68	47.52	48.34	55.20	50.84
Total Debt	38.68	38.68	47.52	216.33	294.02	302.28
Total Liabilities	516.73	488.10	447.70	548.58	634.97	670.27
APPLICATION OF FUNDS :
Gross Block	568.50	578.19	581.73	589.77	674.06	669.01
Less : Accumulated Depreciation	368.82	353.52	337.53	318.30	327.17	299.08
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	199.68	224.67	244.20	271.47	346.89	369.93
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	26.10	25.23	25.11	24.63	64.76	64.76
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	20.27	0.14	0.14	0.14	0.14	0.14
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	113.60	125.63	119.69	136.44	140.94	135.98
Sundry Debtors	84.92	30.41	16.44	29.78	31.39	44.15
Cash and Bank	52.57	49.97	30.24	1.44	1.28	3.64
Loans and Advances	47.10	58.40	47.37	116.28	79.98	64.77
Total Current Assets	298.19	264.41	213.74	283.94	253.59	248.53
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	71.79	81.86	87.14	71.30	72.01	55.87
Provisions	0.89	0.75	0.68	0.61	4.52	1.32
Total Current Liabilities	72.67	82.61	87.82	71.90	76.53	57.19
Net Current Assets	225.52	181.80	125.92	212.04	177.06	191.35
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	32.78	33.49	0.00	0.00	0.00	0.00
Deferred Tax Liability	43.43	32.81	3.63	16.85	14.88	16.03
Net Deferred Tax	-10.65	0.68	-3.63	-16.85	-14.88	-16.03
Total Assets	460.91	432.52	391.74	491.43	573.97	610.15
Contingent Liabilities	31.31	10.63	0.16	0.16	2.52	1.77

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	13.37	13.37	12.34	12.34	12.34	12.34
Reserves Total	446.97	427.08	374.19	311.03	320.18	349.57
Equity Share Warrants	0.00	0.00	13.75	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	460.34	440.45	400.28	323.37	332.52	361.91
Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Secured Loans	3.61	4.06	4.58	172.58	243.26	256.06
Unsecured Loans	38.68	38.78	46.74	47.87	54.73	50.84
Total Debt	42.29	42.84	51.32	220.45	297.99	306.90
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	8.85	7.95	7.66	6.92	5.78	5.00
Total Liabilities	511.48	491.24	459.26	550.74	636.29	673.81
APPLICATION OF FUNDS :
Gross Block	603.75	612.50	616.32	623.96	707.02	703.32
Less: Accumulated Depreciation	387.78	371.57	354.63	334.59	342.57	314.11
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	215.97	240.93	261.69	289.37	364.45	389.21
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	26.10	25.23	25.11	24.63	64.76	64.76
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	20.13	0.00	0.00	0.00	0.00	0.00
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	119.94	125.64	119.99	141.12	142.73	138.17
Sundry Debtors	76.66	38.60	32.04	30.69	38.04	47.27
Cash and Bank	53.72	50.40	31.42	2.13	2.81	3.98
Loans and Advances	52.51	63.40	50.59	120.06	81.86	70.84
Total Current Assets	302.83	278.04	234.03	294.00	265.43	260.27
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	78.07	87.82	92.28	75.57	77.14	59.61
Provisions	0.89	0.75	0.68	0.61	4.52	1.32
Total Current Liabilities	78.96	88.57	92.96	76.18	81.65	60.93
Net Current Assets	223.87	189.47	141.07	217.83	183.78	199.33
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	32.78	33.49	0.00	0.00	0.00	0.00
Deferred Tax Liability	43.43	32.81	3.63	16.85	14.88	16.03
Net Deferred Tax	-10.65	0.68	-3.63	-16.85	-14.88	-16.03
Other Assets	36.06	34.93	35.03	35.77	38.18	36.53
Total Assets
Contingent Liabilities	31.31	10.63	0.16	0.16	2.53	1.77

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	42.83	27.70	1.26	0.50	3.64
Net Cash from Operating Activities	28.05	41.00	132.34	77.75	43.65
Net Cash Used In Investing Activities	-50.81	-16.75	55.98	-4.64	-11.27
Net Cash Used In Financing Activities	0.00	-9.13	-161.88	-72.35	-34.74
Net Inc./Dec In Cash And Cash Equivalents	-22.76	15.12	26.45	0.76	-2.36
Cash And Cash Equivalents At End Of The Year	20.07	42.83	27.70	1.26	1.28

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

41.76%

FII Shareholding

1.48%

DII Shareholding

0.15%

Public Shareholding

56.61%

**Promoter pledged shareholding 41.76%

About Venus Remedies Ltd

Venus Remedies Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 437.3 crores. It has reported a sales of Rs. 131.23 crores and a net profit of Rs. 8.19 crores for the quarter ended December 2018. The company management includes Pawan Chaudhary, Pawan Chaudhary,Manu Chaudhary,Peeyush Jain,Ashutosh Jain,Gilbert Wenzel,S. K. Chadha,Neha Kodan,Navdeep Sud,Savita Gupta,Akshansh Chaudhary,Nps Monga (Venus Remedies Ltd) among others.

Chairman

Pawan Chaudhary

Registered office

S C No 857 Cabin No 10 2nd Flr,N A C Manimajra,Chandigarh,Chandigarh,160101

FAX :

Background

Incorporation Year1989

Face Value₹10

Market Lot1

How to buy Venus Remedies shares on nse?

To buy Venus Remedies shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Venus Remedies share price today?

The Venus Remedies shares price on nse is Rs.327.15 today.

What is the market cap of Venus Remedies shares on BSE ?

The company has a market capitalization of Rs.437.30Cr

What is the PE & PB ratio of Venus Remedies shares ?

PE is 17.14 and PB is 0.9

What is the 52 Week High and Low of Venus Remedies shares?

Venus Remedies stock price high: Rs.429.6 Venus Remedies stock price low: Rs.185.65